AI made execution free. Knowing first is the whole game now.
The advantage goes to whoever is first into the right conversations, most often. Fundz stacks those odds: more of the moments that create demand than anyone else catches, as they happen, matched to who you sell to, with the decision maker to call. Now it answers in Claude too: ask for today’s leads and who to reach, then write the note in the same window. Not a feed. Not a list you rent. A system for being first.
Trusted by
OracleSnowflakeCloudflareLinkedInGoogleSalesforce
★★★★★4.8/5 on G2· Since 2015
ViferaXS raises €12M in Series A led by SPRIND and Huma to advance Phase II trial for chronic lymphocytic leukemia.
ViferaXS, a clinical-stage biotechnology company developing peptide-based cancer immunotherapy, closed a €12 million Series A financing round led by SPRIND and Huma with participation from private investors. The proceeds will fund the company's lead Phase II clinical trial of CLLTAXS01 in chronic lymphocytic leukemia, as well as ongoing Phase I programs in acute myeloid leukemia and fibrolamellar carcinoma. The financing also supports team expansion and preclinical work in additional indications.
Company Information
Company
ViferaXS
Location
Baden Württemberg, Germany
About
ViferaXS GmbH is a clinical-stage biotechnology company based in Tübingen, Germany, developing peptide-based cancer immunotherapies for hematologic malignancies and solid tumors. The company's proprietary T Cell Activator technology is designed to activate cytotoxic T cells against naturally presented tumor antigens. Its clinical pipeline spans three oncology indications: acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), and fibrolamellar carcinoma (FLC). ViferaXS is a spin-out of the Eberhard Karls University Tübingen.
Fundz sees it the moment ViferaXS raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Baden WürttembergBiotechnologyHealth CareTherapeutics